STUDIO CITY, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)INTERNATIONAL MYELOMA FOUNDATION, founded in 1990, is a mid-sized nonprofit in the Unknown sector that reported $19.0M in total revenue in fiscal year 2023. Revenue grew 13% year-over-year, indicating healthy expansion.
DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE.
RESEARCH - THE INTERNATIONAL MYELOMA FOUNDATION (IMF) IS THE LEADER IN GLOBALLY COLLABORATIVE MYELOMA RESEARCH. IMF SUPPORTS LAB-BASED RESEARCH AND HAS AWARDED OVER 156 GRANTS TO TOP JUNIOR AND...
RESEARCH - THE INTERNATIONAL MYELOMA FOUNDATION (IMF) IS THE LEADER IN GLOBALLY COLLABORATIVE MYELOMA RESEARCH. IMF SUPPORTS LAB-BASED RESEARCH AND HAS AWARDED OVER 156 GRANTS TO TOP JUNIOR AND SENIOR RESEARCH SCIENTISTS SINCE 1995. IN ADDITION, IMF BRINGS TOGETHER THE WORLD'S LEADING EXPERTS IN THE MOST SUCCESSFUL AND UNIQUE WAY THROUGH THE INTERNATIONAL MYELOMA WORKING GROUP, WHICH IS PUBLISHING IN PRESTIGIOUS MEDICAL JOURNALS, CHARTING THE COURSE TO A CURE, MENTORING THE NEXT GENERATION OF INNOVATIVE INVESTIGATORS, AND IMPROVING LIVES THROUGH BETTER CARE. IT IS CONSIDERED THE MOST PRESTIGIOUS ORGANIZATION FOR MYELOMA RESEARCHERS GLOBALLY. THE BLACK SWAN RESEARCH INITIATIVE IS A MULTINATIONAL CONSORTIUM OF LEADING MYELOMA EXPERTS WHO ARE HARNESSING NEW TECHNOLOGIES AND THE LATEST MYELOMA TREATMENTS TO FIND A PATHWAY TO A CURE. THE BLACK SWAN RESEARCH STRATEGY CAPITALIZES ON THE AVAILABILITY OF POTENT NOVEL THERAPIES AND THE ADVENT OF ULTRA-SENSITIVE TESTS TO MEASURE EXACTLY WHEN AND HOW THOSE THERAPIES ARE WORKING IN PATIENTS. THE BLACK SWAN RESEARCH INITIATIVE IS DEDICATED TO DEVELOPING NEW CURATIVE THERAPIES FOR MYELOMA.
EDUCATION AND AWARENESS - ALTHOUGH IT IS THE SECOND MOST COMMON BLOOD CANCER, MULTIPLE MYELOMA IS STILL A RELATIVELY UNKNOWN DISEASE. FOR MANY PATIENTS AND THEIR CAREGIVERS, IT IS AT DIAGNOSIS WHEN...
EDUCATION AND AWARENESS - ALTHOUGH IT IS THE SECOND MOST COMMON BLOOD CANCER, MULTIPLE MYELOMA IS STILL A RELATIVELY UNKNOWN DISEASE. FOR MANY PATIENTS AND THEIR CAREGIVERS, IT IS AT DIAGNOSIS WHEN THEY FIRST HEARD THE WORD "MYELOMA". IMF RECOGNIZES THE NEED FOR COMPREHENSIVE EDUCATION PROGRAMS FOR BOTH THE PATIENT AND THE PHYSICIAN TO ENSURE THAT PATIENTS ARE DIAGNOSED CORRECTLY AND TREATED EFFECTIVELY. OUR LIBRARY OF MORE THAN 100 PUBLICATIONS FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, IS AVAILABLE FREE OF CHARGE. PUBLICATIONS ARE UPDATED ANNUALLY AND AVAILABLE IN MORE THAN 19 INTERNATIONAL LANGUAGES. THE IMF EMPOWERS PATIENTS AND THEIR CAREGIVERS TO JOIN HEALTHCARE PROVIDERS AS ACTIVE DECISION-MAKING PARTNERS, LEADING TO THE BEST POSSIBLE QUALITY OF LIFE FOR EACH INDIVIDUAL MYELOMA PATIENT. THE IMF PRODUCES COMPREHENSIVE BUT 'USER-FRIENDLY' INFORMATION FOR THE ENTIRE MYELOMA COMMUNITY. THE IMF'S PUBLICATIONS LIBRARY INCLUDES AN EXTENSIVE CATALOG OF BOOKLETS, TIP CARDS, ARTICLES, WEBINARS AND TELECONFERENCES, BLOGS, DIGITAL MEDIA AND INTERVIEWS, ALL WRITTEN, CREATED, AND PRODUCED BY THE IMF WITH OVERSIGHT BY ITS SCIENTIFIC ADVISORY COMMITTEE. THE IMF LIBRARY'S BROAD SCOPE INCLUDES INFORMATION ABOUT MYELOMA TREATMENT OPTIONS, CLINICAL TRIALS, DIVERSITY, EQUITY AND QUALITY OF LIFE CONSIDERATIONS FOR PATIENTS AND PHYSICIANS.
PATIENT AND FAMILY SEMINARS: THE IMF'S PATIENT AND FAMILY SEMINARS PRESENT VITAL INFORMATION ABOUT NEW TREATMENTS AND CLINICAL TRIALS, PROVIDE TIME WITH MYELOMA SPECIALISTS IN INTIMATE SETTINGS, AND...
PATIENT AND FAMILY SEMINARS: THE IMF'S PATIENT AND FAMILY SEMINARS PRESENT VITAL INFORMATION ABOUT NEW TREATMENTS AND CLINICAL TRIALS, PROVIDE TIME WITH MYELOMA SPECIALISTS IN INTIMATE SETTINGS, AND ALLOW PARTICIPANTS TO SHARE THEIR PERSONAL EXPERIENCES AND SUPPORT. PREMIER MYELOMA EXPERTS VOLUNTEER THEIR TIME TO THE SEMINARS, TO EMPOWER PATIENTS AND THEIR FAMILIES TO MAKE EDUCATED TREATMENT CHOICES TAILORED TO THEIR NEEDS. IN ADDITION TO PATIENT AND FAMILY SEMINARS, THE IMF FACILITATES REGIONAL COMMUNITY WORKSHOPS, WHICH SERVE AS CONDENSED SEMINARS IN SMALLER CITIES TO EXPAND THE REACH OF IMF PROGRAMS AND UP-TO-DATE INFORMATION ON MYELOMA CARE, SUPPORT AND TREATMENT TO A WIDER AUDIENCE AT NO CHARGE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $18,983,815 | $16,745,686 | +0.1% |
| Expenses | $20,796,076 | $18,411,117 | +0.1% |
| Net Income | $-1,812,261 | $-1,665,431 | +0.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| YELAK BIRU | CEO, PRESIDENT, DIRECTOR | 40.00 |
Officer
Director
|
$430,000 | $20,698 | $450,698 |
| CHRISTINE BATTISTINI | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| LORAINE BOYLE | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MARTINE ELIAS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| GEORGE T HAYUM | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JASON KATZ | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| BENSON KLEIN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ANDREW KUZNESKI III | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DR HEINZ LUDWIG | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CHARLES NEWMAN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MATTHEW ROBINSON | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DR VINCENT RAJKUMAR | CHAIRMAN | 40.00 |
Director
|
$0 | $0 | $0 |
| E MICHAEL SCOTT | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SANJAY SINGH | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JOHN O'DWYER | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| POORNIMA PARAMESWARAN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JENNIFER SCARNE | CHIEF FINANCIAL OFFICER | 40.00 |
Officer
|
$303,088 | $22,273 | $325,361 |
| PETER ANTON | VICE PRESIDENT, MARKETING | 40.00 |
Key Emp
|
$225,894 | $31,563 | $257,457 |
| ROBIN TUOHY | VICE PRESIDENT, PATIENT SUPPORT | 40.00 |
Key Emp
|
$179,562 | $32,574 | $212,136 |
| SUSAN DURIE | DIRECTOR OF GLOBAL PATIENT EMPOWERMENT-FORMER DIR | 40.00 |
Highest
|
$362,646 | $27,940 | $390,586 |
| DR BRIAN DURIE | CHIEF SCIENTIFIC OFFICER-FORMER DIR | 40.00 |
Highest
|
$430,000 | $3,096 | $433,096 |
| DIANE MORAN | SENIOR VICE PRESIDENT - BUSINESS RELATIONSHIP MANA | 40.00 |
Highest
|
$432,784 | $15,830 | $448,614 |
| LISA PAIK | EXECUTIVE VICE PRESIDENT - RESEARCH & OPERATIONS | 40.00 |
Highest
|
$275,225 | $26,338 | $301,563 |
| JOSEPH MIKHAEL | CHIEF MEDICAL OFFICER | 40.00 |
Highest
|
$459,562 | $18,845 | $478,407 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | $18,983,815 | $20,796,076 | $16,882,003 | $-1,812,261 |
| 2023 | $16,745,686 | $18,411,117 | $18,245,423 | $-1,665,431 |
| 2022 | $18,062,675 | $16,819,032 | $18,463,467 | $1,243,643 |
| 2021 | $17,434,390 | $14,439,887 | $20,383,236 | $2,994,503 |
| 2020 | $14,864,659 | $14,722,445 | $17,342,878 | $142,214 |
| 2020 | $14,864,659 | $14,507,444 | $17,557,878 | $357,215 |
| 2019 | $20,025,618 | $19,330,926 | $18,014,619 | $694,692 |
| 2018 | $16,804,022 | $16,883,907 | $16,649,778 | $-79,885 |
Compare INTERNATIONAL MYELOMA FOUNDATION with other nonprofits in California and across the country.